|
|
|
|
|||||
|
|
|
New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves
Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the 10 Best Debt Free Small Cap Stocks to Buy Now.
On September 11, 2025, H.C. Wainwright reiterated its ‘Buy’ rating on Anavex Life Sciences Corp. (NASDAQ:AVXL) with a $42 price target. This bullish stance follows new Phase 2b/3 Alzheimer’s data.
Anavex Life Sciences Corp. (NASDAQ:AVXL)’s shares are currently trading well below this target, indicating significant upside potential. Meanwhile, the company announced on September 9, 2025, that its oral therapy blarcamesine noted reduced cognitive decline across key measures in early Alzheimer’s patients. This bolsters confidence in the company’s precision medicine approach.
Anavex Life Sciences Corp. (NASDAQ:AVXL), a biopharmaceutical company, develops novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. It is one of the Best Debt Free Stocks.
While we acknowledge the potential of AVXL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.
Disclosure: None.
| Oct-10 | |
| Oct-02 | |
| Oct-02 | |
| Sep-30 | |
| Sep-24 | |
| Sep-09 | |
| Sep-02 | |
| Aug-26 | |
| Aug-20 | |
| Aug-20 | |
| Aug-13 | |
| Aug-12 | |
| Aug-12 | |
| Aug-05 | |
| Aug-01 |
Anavexs blarcasemine nets win in Phase IIb/III Alzheimers extension study
AVXL
Clinical Trials Arena
|
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite